Literature DB >> 20590859

von Willebrand's disease diagnosis and laboratory issues.

G Castaman1, R R Montgomery, S S Meschengieser, S L Haberichter, A I Woods, M A Lazzari.   

Abstract

SUMMARY: In this paper, the recent developments in the diagnosis and laboratory issues of von Willebrand's disease (VWD) are presented. Dr. Castaman reviews the functional tests available for the diagnosis of VWD and their pathophysiological significance, focusing on which tests are best used in the diagnosis and classification of VWD. Dr Montgomery reviews an emerging issue that is accelerated clearance of von Willebrand factor (VWF) occurring in some variants of VWD. This phenotype can be suspected by the presence of an increased ratio between the VWF propeptide and the VWF antigen. These patients have typically a robust, but short-lived increase of FVIII and VWF after desmopressin. Dr Meschengieser reviews the determinants of bleeding after surgery in patients with VWD, emphasizing the role of bleeding history in predicting this risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590859      PMCID: PMC4313748          DOI: 10.1111/j.1365-2516.2010.02296.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  40 in total

1.  Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease--single center comparison of four different assays.

Authors:  A B Federici; M T Canciani; I Forza; G Cozzi
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Von Willebrand's disease in Italy. A study of 13 families from a small area in the province of Vicenza.

Authors:  E Dini; T Barbui; T Chisesi; M Cazzavillan; R Battista; G Cartei
Journal:  Acta Haematol       Date:  1974       Impact factor: 2.195

3.  Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.

Authors:  G Castaman; A B Federici; M Bernardi; B Moroni; K Bertoncello; F Rodeghiero
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

4.  The RIIIS/J inbred mouse strain as a model for von Willebrand disease.

Authors:  J D Sweeney; E K Novak; M Reddington; K H Takeuchi; R T Swank
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

5.  Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents.

Authors:  Claudine Caron; Claudine Mazurier; Jenny Goudemand
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

6.  Von Willebrand disease as cause of unanticipated bleeding following adeno-tonsillectomy.

Authors:  J I de Diego; M P Prim; E Rodriguez; J Garcia; M Morado
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1999-08-20       Impact factor: 1.675

7.  von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene.

Authors:  W C Nichols; K A Cooney; K L Mohlke; J D Ballew; A Yang; M E Bruck; M Reddington; E K Novak; R T Swank; D Ginsburg
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

8.  Major surgery (radical cystectomy with urethrectomy) in a patient with von Willebrand's disease type I. Reliability and limits of hemocoagulative tests.

Authors:  M Favro; C Terrone; D Neira; S R Rossetti; M M Schellino; S Livigni; A Tempia
Journal:  Minerva Urol Nefrol       Date:  1998-12       Impact factor: 3.720

Review 9.  An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.

Authors:  Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2007-11       Impact factor: 4.180

10.  Bleeding manifestations in males with von Willebrand disease.

Authors:  O Ziv; M V Ragni
Journal:  Haemophilia       Date:  2004-03       Impact factor: 4.287

View more
  5 in total

1.  von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.

Authors:  Sri R Madabhushi; Chengwei Shang; Kannayakanahalli M Dayananda; Kate Rittenhouse-Olson; Mary Murphy; Thomas E Ryan; Robert R Montgomery; Sriram Neelamegham
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

Review 2.  Clinical and laboratory approaches to hemophilia a.

Authors:  Hassan Mansouritorghabeh
Journal:  Iran J Med Sci       Date:  2015-05

3.  Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding.

Authors:  Massimo Cugno; Alberto Tedeschi; Simona Maria Siboni; Francesca Stufano; Federica Depetri; Franca Franchi; Samantha Griffini; Flora Peyvandi
Journal:  Exp Hematol Oncol       Date:  2014-06-04

4.  Diagnosis of congenital von Willebrand disease during a preoperative assessment in a multiple myeloma patient without bleeding history.

Authors:  Malika El Ouaaliti; Rong Li; Delphine Gobin; Dominique Bron; Brigitte Cantinieaux
Journal:  Clin Case Rep       Date:  2016-06-13

5.  Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity.

Authors:  Y Ni; J Nesrallah; M Agnew; F J Geske; E J Favaloro
Journal:  Int J Lab Hematol       Date:  2012-10-29       Impact factor: 2.877

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.